SVT 1C4610
Alternative Names: SVT-1C4610Latest Information Update: 06 Nov 2022
At a glance
- Originator Servatus Biopharmaceuticals
- Class Antibacterials; Bacteria
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Helicobacter infections
Most Recent Events
- 01 Oct 2022 SVT 1C4610 is available for licensing as of 01 Oct 2022. https://servatus.com.au/our-research/ (Servatus Biopharmaceuticals pipeline, October 2022)
- 01 Oct 2022 Phase-I clinical trials in Helicobacter infections in Australia (unspecified route) (Servatus Biopharmaceuticals pipeline, October 2022)